Xeris Biopharma Holdings Inc
XERS
Market Cap$252.03M
Close$
$2.89
65.2% upside
Current Fair Value
65.2% upsideUndervalued by 65.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $252.03 Million |
|---|---|
| Enterprise Value | $408.77 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.45 |
| Beta | 0.0 |
| Outstanding Shares | 148,253,615 |
| Avg 30 Day Volume | 1,436,829 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.05 |
|---|---|
| PEG | -113.8 |
| Price to Sales | 1.75 |
| Price to Book Ratio | -1.75 |
| Enterprise Value to Revenue | 2.49 |
| Enterprise Value to EBIT | -9.29 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.56 |
| Debt to Equity | -33.79 |
Revenue Sources
No data
ESG Score
No data
About Xeris Pharmaceuticals Inc
CEO: paul Edick